A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Run by AstraZeneca · NCT05120349 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-08-02.
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 390 (actual) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | Osimertinib, Placebo |
| Locations | 139 sites (Argentina, Brazil, Canada, China, Germany, Italy, Japan, Malaysia and more) |
| Trial ID | NCT05120349 on ClinicalTrials.gov |
What this trial studies
This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R). Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Male or female, at least ≥ 18 years. 2. NSCLC, of non-squamous histology. 3. Stage IA2 or IA3 disease, based on TNM8 classification. 4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection. 5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants. 6. World Health Organization performance status of 0 or 1. 7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation. 8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test. 9. Minimum life expectancy of \> 6 months. 10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception. Exclusion Criteria 1. Mixed small cell and non-small cell cancer history. 2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection. 3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection. 4. History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence. 5. Any of the following cardiac criteria: * Mean resting QTcF interval \> 470 ms, obtained from triplicate ECGs performed at screening. * Any abnormalities in rhythm, conduction, or morphology of resting ECG, * Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events. 6. History of interstitial lung disease. 7. Inadequate bone marrow reserve or organ function. 8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention. 9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs). 10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention. 11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.
Where it's running
-
Research Site
Anchorage, Alaska, United States -
Research Site
Los Angeles, California, United States -
Research Site
Orange, California, United States -
Research Site
Grand Junction, Colorado, United States -
Research Site
Newark, Delaware, United States -
Research Site
Atlanta, Georgia, United States
Show 44 more locations
-
Research Site
Chicago, Illinois, United States -
Research Site
Frederick, Maryland, United States -
Research Site
Morristown, New Jersey, United States -
Research Site
Flushing, New York, United States -
Research Site
New York, New York, United States -
Research Site
New York, New York, United States -
Research Site
White Plains, New York, United States -
Research Site
Houston, Texas, United States -
Research Site
Fort Belvoir, Virginia, United States -
Research Site
Buenos Aires, Argentina -
Research Site
Caba, Argentina -
Research Site
Cipolletti, Argentina -
Research Site
La Plata, Argentina -
Research Site
Rosario, Argentina -
Research Site
Rosario, Argentina -
Research Site
S.C. de Bariloche, Argentina -
Research Site
Barretos, Brazil -
Research Site
Belo Horizonte, Brazil -
Research Site
Porto Alegre, Brazil -
Research Site
Recife, Brazil -
Research Site
Rio de Janeiro, Brazil -
Research Site
São Paulo, Brazil -
Research Site
São Paulo, Brazil -
Research Site
Vancouver, British Columbia, Canada -
Research Site
Montreal, Quebec, Canada -
Research Site
Toronto, Canada -
Research Site
Beijing, China -
Research Site
Beijing, China -
Research Site
Beijing, China -
Research Site
Beijing, China -
Research Site
Beijing, China -
Research Site
Beijing, China -
Research Site
Changchun, China -
Research Site
Changsha, China -
Research Site
Changsha, China -
Research Site
Chengdu, China -
Research Site
Fuzhou, China -
Research Site
Guangzhou, China -
Research Site
Guangzhou, China -
Research Site
Hangzhou, China -
Research Site
Harbin, China -
Research Site
Jinan, China -
Research Site
Nanjing, China -
Research Site
Shanghai, China
+89 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Jonathan Goldman, MD — University of California, Los Angeles
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Osimertinib with Cyclosporine A for EGFR-mutant NSCLC
This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.
-
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic NSCLC
This trial tests whether surgically removing the main lung tumor, after initial osimertinib therapy, helps people with EGFR-mutant oligometastatic non-small cell lung cancer live longer without disease progression.
-
Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options
This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.
-
BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC
A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.
-
BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation
This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.